Cormorant Asset Management CBAY Position
Exited7-Fund ConvergenceCormorant Asset Management exited their position in CymaBay Therapeutics Inc. (CBAY) in Q1 2024, after holding the stock for 5 quarters.
The position was first reported in Q1 2023 and has been tracked across 5 quarterly 13F filings.
CBAY is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
About CymaBay Therapeutics Inc.
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Full company profile →Cormorant Asset Management CBAY Position History
Frequently Asked Questions
Does Cormorant Asset Management own CBAY?
No. Cormorant Asset Management exited their position in CymaBay Therapeutics Inc. (CBAY) in Q1 2024. They previously held the stock for 5 quarters.
How many hedge funds own CBAY?
7 specialist biotech hedge funds currently hold CBAY, including Avoro Capital Advisors, RA Capital Management, Perceptive Advisors and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Cormorant Asset Management first buy CBAY?
Cormorant Asset Management's position in CBAY was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Cormorant Asset Management's CBAY position increasing or decreasing?
Cormorant Asset Management completely exited their CBAY position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CBAYCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Cormorant Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →